Cryo-Cell International, Inc. (CCEL) P/E Ratio History
Deep ValueTrading at -10.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2001–2025
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Cryo-Cell International, Inc. (CCEL) trades at a price-to-earnings ratio of -10.6x, with a stock price of $3.17 and trailing twelve-month earnings per share of $-0.33.
The current P/E is 115% below its 5-year average of 71.5x. Over the past five years, CCEL's P/E has ranged from a low of 12.0x to a high of 790.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, CCEL trades at a 146% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, CCEL trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CCEL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CCEL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CCEL P/E vs Peers
Healthcare staffing and facility services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 144.5 | 3.66 | +60%Best | |
| $56B | 26.7Lowest | 1.62Best | -1% | |
| $11B | 154.3 | - | -56% | |
| $5B | 33.2 | 3.81 | -16% | |
| $2B | 38.0 | 1.96 | +31% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CCEL Historical P/E Data (2001–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Feb 28 2025 | $7.90 | $0.01 | 790.0x | +812% |
| FY2024 Q4 | Nov 30 2024 | $8.67 | $0.05 | 182.9x | +111% |
| FY2023 Q3 | - | $6.00 | $0.30 | 20.0x | -77% |
| FY2023 Q2 | May 31 2023 | $4.85 | $0.28 | 17.6x | -80% |
| FY2023 Q1 | - | $3.82 | $0.32 | 12.0x | -86% |
| FY2022 Q4 | Nov 30 2022 | $4.37 | $0.32 | 13.5x | -84% |
| FY2022 Q3 | Aug 31 2022 | $7.37 | $0.15 | 47.6x | -45% |
| FY2022 Q2 | - | $6.13 | $0.20 | 30.8x | -65% |
| FY2022 Q1 | Feb 28 2022 | $8.13 | $0.27 | 30.7x | -65% |
| FY2021 Q4 | - | $12.38 | $0.25 | 49.5x | -43% |
| FY2021 Q3 | - | $11.60 | $0.48 | 24.2x | -72% |
| FY2021 Q2 | May 31 2021 | $8.65 | $0.48 | 18.0x | -79% |
| FY2021 Q1 | Feb 28 2021 | $10.00 | $0.46 | 21.7x | -75% |
| FY2020 Q4 | Nov 30 2020 | $7.50 | $0.46 | 16.3x | -81% |
| FY2020 Q3 | Aug 31 2020 | $8.37 | $0.41 | 20.4x | -76% |
| FY2020 Q2 | May 31 2020 | $7.40 | $0.44 | 16.8x | -81% |
| FY2020 Q1 | Feb 29 2020 | $7.16 | $0.33 | 21.7x | -75% |
| FY2019 Q4 | Nov 30 2019 | $7.55 | $0.28 | 27.0x | -69% |
| FY2019 Q3 | Aug 31 2019 | $7.53 | $0.28 | 26.9x | -69% |
| FY2019 Q2 | May 31 2019 | $7.70 | $0.18 | 42.8x | -51% |
| FY2019 Q1 | - | $6.55 | $0.24 | 27.3x | -69% |
| FY2017 Q4 | - | $8.06 | $0.31 | 26.4x | -70% |
| FY2017 Q3 | - | $6.75 | $0.33 | 20.5x | -76% |
| FY2016 Q2 | - | $3.00 | $0.83 | 3.6x | -96% |
| FY2016 Q1 | Feb 29 2016 | $3.75 | $0.78 | 4.8x | -94% |
| FY2015 Q4 | Nov 30 2015 | $3.30 | $0.83 | 4.0x | -95% |
| FY2015 Q3 | Aug 31 2015 | $3.39 | $0.82 | 4.1x | -95% |
| FY2015 Q2 | May 31 2015 | $2.36 | $0.04 | 59.1x | -32% |
| FY2015 Q1 | Feb 28 2015 | $2.45 | $0.04 | 61.4x | -29% |
| FY2014 Q4 | Nov 30 2014 | $2.78 | $0.05 | 55.7x | -36% |
| FY2014 Q3 | Aug 31 2014 | $2.95 | $0.06 | 45.9x | -47% |
| FY2014 Q2 | May 31 2014 | $2.45 | $0.06 | 38.1x | -56% |
| FY2014 Q1 | Feb 28 2014 | $2.28 | $0.02 | 103.6x | +20% |
| FY2013 Q4 | Nov 30 2013 | $1.85 | $0.00 | 925.0x | +968% |
| FY2011 Q2 | - | $3.67 | $0.26 | 13.9x | -84% |
| FY2011 Q1 | Feb 28 2011 | $2.00 | $0.28 | 7.1x | -92% |
| FY2010 Q4 | - | $2.20 | $0.29 | 7.5x | -91% |
| FY2010 Q3 | - | $0.90 | $0.24 | 3.8x | -96% |
| FY2010 Q2 | May 31 2010 | $1.25 | $0.08 | 16.4x | -81% |
| FY2010 Q1 | Feb 28 2010 | $1.51 | $0.12 | 13.0x | -85% |
| FY2009 Q4 | Nov 30 2009 | $1.75 | $0.14 | 12.8x | -85% |
| FY2009 Q3 | Aug 31 2009 | $2.32 | $0.17 | 13.5x | -84% |
| FY2009 Q2 | May 31 2009 | $1.25 | $0.12 | 10.8x | -88% |
| FY2009 Q1 | Feb 28 2009 | $0.60 | $0.02 | 38.2x | -56% |
| FY2006 Q2 | May 31 2006 | $2.55 | $0.01 | 359.2x | +314% |
| FY2006 Q1 | - | $3.45 | $0.09 | 37.9x | -56% |
| FY2005 Q4 | Nov 30 2005 | $3.57 | $0.08 | 43.4x | -50% |
| FY2005 Q3 | Aug 31 2005 | $2.91 | $0.10 | 30.5x | -65% |
| FY2005 Q2 | - | $3.60 | $0.20 | 18.4x | -79% |
| FY2005 Q1 | Feb 28 2005 | $2.75 | $0.24 | 11.7x | -87% |
| FY2004 Q4 | - | $2.70 | $0.25 | 11.0x | -87% |
| FY2002 Q2 | May 31 2002 | $4.32 | $0.10 | 41.9x | -52% |
| FY2002 Q1 | - | $4.65 | $0.19 | 24.9x | -71% |
| FY2001 Q4 | Nov 30 2001 | $6.42 | $0.15 | 41.5x | -52% |
| FY2001 Q3 | Aug 31 2001 | $8.15 | $0.01 | 1198.5x | +1283% |
Average P/E for displayed period: 86.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CCEL — Frequently Asked Questions
Quick answers to the most common questions about buying CCEL stock.
What is CCEL's P/E ratio?
Cryo-Cell International, Inc. (CCEL) trailing twelve-month P/E ratio is -10.6x, based on TTM diluted EPS of $-0.33. The 5-year average P/E is 71.5x and the historical range spans 12.0x to 790.0x.
Is CCEL stock overvalued or undervalued?
CCEL trades at -10.6x P/E, below its 5-year average of 71.5x. At the 0th percentile of its historical range (12.0x–790.0x), the stock is priced at a discount to its own history.
Is CCEL stock expensive?
No, CCEL is not expensive on a historical basis. The current P/E of -10.6x is below the 5-year average of 71.5x and sits at the 0th percentile of its valuation range.
What is CCEL's historical P/E range?
Over the past 5 years, CCEL's P/E ratio has ranged from 12.0x to 790.0x, with a median of 24.2x and an average of 71.5x. The current P/E of -10.6x places the stock at the 0th percentile of this range. Full historical data spans 2001–2025.
How does CCEL's P/E compare to the S&P 500?
CCEL trades at -10.6x P/E versus the S&P 500 median of 25.3x. The 142% discount to the market suggests lower growth expectations or perceived higher risk.
How does CCEL's valuation compare to Healthcare peers?
Cryo-Cell International, Inc. P/E of -10.6x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CCEL's PEG ratio?
CCEL PEG ratio is N/A, based on a P/E of -10.6x and EPS growth of -700.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CCEL's earnings yield?
CCEL earnings yield is N/A, the inverse of its -10.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.